G

ood morning, everyone. Damian Garde here, in for Ed Silverman, with your roundup of tidbits from the world of pharma. So begins another week, with the attendant meetings, deadlines, and interminable conference calls. For those of you soon staring down a blizzard, stay warm out there, and do drop us a line if you hear something interesting.

Dr. Scott Gottlieb is the man on deck to lead President Donald Trump’s FDA, a long-suspected bit of news that was made official Friday night. Gottlieb was the establishment choice among the cast of characters under consideration, and he comes to the agency with a mandate to speed up the drug approval process. The pick drew bipartisan praise and was widely celebrated by the drug industry, but Gottlieb’s close ties to pharma could be a drag on Senate confirmation, as was the case for his predecessor.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.